Search

Displaying results 7281 - 7290 of 7655 in total
  1. Drug

    Dersalazine

    go.drugbank.com/drugs/DB06251
    Investigational

  2. Drug

    Refametinib

    go.drugbank.com/drugs/DB06309
    Investigational

  3. Drug

    Naxifylline

    go.drugbank.com/drugs/DB06471
    Experimental

  4. Drug

    MLN2222

    go.drugbank.com/drugs/DB06503
    Experimental

    MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.

  5. Drug

    Temanogrel

    go.drugbank.com/drugs/DB05227
    Investigational

    APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena. APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constricti...

  6. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). It is being developed by Exelixis, Inc.

  7. Drug

    Ostabolin-C

    go.drugbank.com/drugs/DB05536
    Investigational

    Ostabolin C was under investigation in clinical trial NCT00787358 (A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women (SHIFT)).

  8. Drug

    AVI-4065

    go.drugbank.com/drugs/DB05620
    Investigational

    AVI-4065, a phosphorodiamidate Morpholino oligomer (PMO), is an investigational antisense HCV drug. It was developed by Sarepta Therapeutics, Inc. After phase II trials it was cancelled due to lack of potency.

  9. Drug

    Valtorcitabine

    go.drugbank.com/drugs/DB06187
    Investigational

  10. Drug

    Celgosivir

    go.drugbank.com/drugs/DB06580
    Investigational